Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial

Alipour, Sadaf and Abedi, Mahboubeh and Saberi, Azin and Maleki-Hajiagha, Arezoo and Faiz, Firoozeh and Shahsavari, Saeed and Eslami, Bita (2021) Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial. BMC Endocrine Disorders, 21 (169). ISSN 1472-6823

PDF Download (207kB)

Abstract

Background: Fibroadenoma (FA) is the most common benign solid breast mass in women, with no definite method of management. Because fibroadenoma is dependent on female sex hormones and comprises hypertrophic changes at cellular levels, we investigated the effects of metformin (MF), a safe hypoglycemic agent with anti-estrogenic and anti-proliferative properties, in the management of fibroadenoma. Methods: In this randomized clinical trial study, eligible women with fibroadenomas were assigned randomly to the metformin (1000 mg daily for six months) or the placebo group. Breast physical and ultrasound exam was performed before and after the intervention, and the changes in the size of fibroadenomas were compared in the two groups. Results: Overall, 83 patients in the treatment, and 92 in the placebo group completed the study. A statistically significant difference in changing size between the two groups was observed only in the smallest mass. In the largest FAs, the rate of size reduction was higher in the treatment group (60.2 % vs. 43.5 %); while a higher rate of enlargement was observed in the placebo group (38 % vs. 20.5 %). In the smallest FAs, the rate of the masses that got smaller or remained stable was about 90 % in the treatment group and 50 % in the placebo group. We categorized size changes of FAs into < 20 % enlargement and ≥ 20 % enlargement. The odds ratio (OR) for an elargemnt less than 20% was 1.48 (95 % CI = 1.10–1.99) in the treatment group in comparison with the placebo group; the odds for an enlargement less than 20% was higher in women with multiples fibroadenomas (OR = 4.67, 95 % CI: 1.34–16.28). In our study, no serious adverse effect was recorded, and the medicine was well-tolerated by all users. Conclusions: This is the first study that evaluates the effect of MF on the management of fibroadenoma, and the results suggest a favorable effect. Larger studies using higher doses of MF and including a separate design for patients with single or multiple FAs are suggested in order to confirm this effect.

Item Type:	Article
Subjects:	R Medicine > R Medicine (General) R Medicine > RN Health R Medicine > RS Pharmacy and materia medica
Divisions:	University Portal > research center > hpsr
Depositing User:	pr hpsr research center
Date Deposited:	20 Oct 2021 07:06
Last Modified:	20 Oct 2021 07:06
URI:	http://eprints.qums.ac.ir/id/eprint/11045

Actions (login required)

View Item